Gritstone bio, Inc. — Cyborg Score 2/10

Strategic Profile

The company's two oncology programs in clinical-stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has also developed a COVID-19 vaccine candidate supported by U.S. government contracts and is researching a functional cure for HIV in collaboration with the National Institutes of Health.

Cyborg Score Rationale

The company filed for Chapter 11 bankruptcy in October 2024. Market capitalization stands at $3.8M with the stock declining 98.3% over the past year. The platform and pipeline remain scientifically interesting but company viability is severely compromised.

Top Insights

• Proprietary samRNA and ChAd vector platforms target cancer neoantigens and infectious diseases
• Significant financial deterioration: Chapter 11 bankruptcy filed (October 2024), stock down 98.3% year-over-year
• Market cap collapsed to $3.8M as of early 2025; company now trading on OTC markets
• Government partnerships (NIH, U.S. contracts) on COVID-19 and HIV programs represent residual asset value

Named Competitors

• Moderna — mRNA-based therapeutics and vaccines
• BioNTech — Personalized neoantigen immunotherapies
• Inovio — DNA vaccine platform

Recent Developments

• (October 2024) Filed for Chapter 11 bankruptcy
• Stock price declined to penny stock levels (below $0.05 by late 2024)
• Institutional ownership dropped to zero as of most recent quarter

Open the full interactive Gritstone bio, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.